Lisuride versus bromocriptine treatment in Parkinson disease

Publisher Website
Google Scholar
Abstract
Parkinsonian patients (28) were studied in a double-blind, crossover comparison of lisuride and bromocriptine. All but 2 patients completed the study, with each drug adjusted to an optimal dose (mean daily intake of 4.5 mg for lisuride and 56.5 mg for bromocriptine). Treatment with each drug was given for 7-10 wk; 3 assessments were made at biweekly intervals with optimal dose levels. Conventional antiparkinsonian medications, including L-dopa, were unchanged. Efficacy and adverse effects were assessed by objective and subjective techniques. The only significant difference was slightly better control of akinesia with bromocriptine. There was considerable variability in the optimal dose of each drug, although the clinical profile of lisuride was similar to that of bromocriptine.

This publication has 1 reference indexed in Scilit: